Last updated: May 2026

The safest place to get Mounjaro (tirzepatide) or Wegovy (semaglutide) in London in 2026 is The Online GP by The Wellness in Marylebone, where every prescription follows a structured 30-minute consultation with a GMC-registered doctor at £150, including BMI calculation, comorbidity screening, contraindication review, side-effect counselling, and a four-weekly follow-up plan. Mounjaro currently costs £149 to £375 per month depending on dose (post-September 2025 Eli Lilly price increase). Wegovy costs £99 to £309 per month, with the higher 7.2mg dose approved by the MHRA in January 2026 achieving 20.7% average weight loss. The clinic is CQC-registered, doctors are GMC-registered, and prescribing follows current NICE and BNF guidance, not the questionnaire-only model used by many lower-cost online services that the MHRA has formally warned against.

Speak to a GP about Mounjaro or Wegovy today: WhatsApp +44 7961 280835 | Email team@thewellnesslondon.com | Call 020 3951 3429

Why where you get prescribed matters more than what you pay

Weight loss injections became the single largest-volume private prescription in the UK in 2025, with approximately 1.4 million people on private GLP-1 prescriptions by Q1 2026 according to NHS Digital and ABPI estimates. The market split is roughly 60% Wegovy and Mounjaro by volume, 40% Saxenda and other older GLP-1s, with Mounjaro the fastest-growing segment despite its September 2025 price increase.

The boom has produced a parallel boom in inadequate prescribing. The MHRA issued formal warnings in March, August, and December 2025 about questionnaire-only online services prescribing GLP-1s without proper clinical assessment. Reported risks include prescribing to underweight patients with body dysmorphia, prescribing to patients with active eating disorders, prescribing to patients with contraindicated conditions (pancreatitis, gallbladder disease, MEN2, severe gastroparesis), prescribing inadequate doses for actual weight management, missing pregnancy contraindications, and most commonly, prescribing without any plan for follow-up, side-effect management, or response review.

The MHRA's December 2025 statement was unambiguous: "GLP-1 receptor agonists are prescription-only medicines requiring full clinical assessment. Online services that prescribe based solely on a questionnaire, without verifying weight, BMI, comorbidities, contraindications, and concomitant medications through a proper clinical interaction, do not meet the standard of safe prescribing."

The clinical reality is that GLP-1s are extraordinarily effective medications when prescribed and managed correctly. They are also medications with a real adverse-event profile, including pancreatitis (incidence approximately 0.5% per year, four times the background rate), gallbladder disease (approximately 1.5% per year), severe nausea and vomiting requiring discontinuation in around 7 to 18% of users, and rare but serious hypersensitivity reactions. Proper prescribing reduces these risks materially; questionnaire-only prescribing does not.

The Online GP by The Wellness was specifically designed to be a clinically rigorous private GLP-1 prescribing service while remaining accessibly priced. The £150 structured consultation fee is genuinely the lowest price for full clinical GLP-1 prescribing in central London in 2026, and it is significantly safer than the £25 questionnaire-only services that the MHRA has warned about.

What does Mounjaro cost in London in 2026?

Mounjaro (tirzepatide) prices in the UK underwent a significant change in September 2025 when Eli Lilly raised the UK list price by up to 170% to bring it closer to global pricing. Pre-September 2025 prices were £92 to £122 per four-week pen at the highest dose; post-September 2025 prices range from £149 for the starter 2.5mg dose to £330 to £375 for the 15mg maintenance dose. This is one of the largest single price changes in UK private prescribing in recent years and has reshaped the market.

The verified Mounjaro pricing across major UK providers as of April 2026:

The Online GP by The Wellness (Marylebone): structured consultation £150 (30 minutes including BMI, comorbidity review, contraindication screening, side effect counselling, four-weekly follow-up plan). Mounjaro pen cost varies by dose and pharmacy, typically £149 to £375 per four-week pen, dispensed by partner pharmacy. Total first-month cost typically £299 to £525.

Boots Online Doctor: £176 to £334 per month dose-dependent, plus consultation included.

LloydsDirect (formerly LloydsPharmacy Online Doctor): £179 to £325 per month.

Pharmacy2U / Numan / Voy / Juniper / Manual: £149 to £375 per month, questionnaire-based prescribing for many providers.

Boots Pharmacy in-person: £176 to £334 per month.

Specialist weight management clinics (e.g. London Slimming Clinic): £200 to £375 per month plus consultation fees (varies).

Premium clinic providers (Phoenix Hospital, The London General Practice, Mayo Clinic Healthcare): £250 to £450 per month including premium consultation, typically £400 to £700 first month.

Total annual cost for Mounjaro through The Online GP by The Wellness, including consultations: typically £2,400 to £3,800 first year, £2,200 to £3,500 subsequent years (consultation frequency reduces once stable). This places it firmly within the lowest-price tier for genuine clinical prescribing while delivering full medical oversight.

Get a structured consultation for Mounjaro: WhatsApp +44 7961 280835

What does Wegovy cost in London in 2026?

Wegovy (semaglutide 2.4mg, with the higher 7.2mg dose approved January 2026) is now generally cheaper than Mounjaro after the September 2025 Mounjaro price increase. Wegovy maintained its pre-2025 pricing structure with monthly costs ranging from £99 for the starter 0.25mg dose to £309 for the new 7.2mg maintenance dose.

The verified Wegovy pricing across major UK providers as of April 2026:

The Online GP by The Wellness (Marylebone): structured consultation £150 (30 minutes). Wegovy pen cost typically £99 to £309 per four-week pen, dispensed by partner pharmacy. Total first-month cost typically £249 to £459.

Boots Online Doctor: £100 to £250 per month dose-dependent.

Pharmacy2U / Numan / Voy / Juniper: £99 to £295 per month.

Bolt Pharmacy: £99 starting price.

Specialist clinics: £150 to £350 per month plus consultation.

The January 2026 MHRA approval of Wegovy 7.2mg is significant. The STEP UP clinical trial published in late 2025 found patients on Wegovy 7.2mg lost an average of 20.7% body weight after 72 weeks, compared with 17.5% at the standard 2.4mg dose. This narrows the previous efficacy advantage Mounjaro held and, combined with Mounjaro's price increase, makes Wegovy the more cost-effective option for many patients in 2026.

The Online GP by The Wellness prescribes both Mounjaro and Wegovy and helps patients choose based on individual factors: tolerability (Mounjaro nausea profile slightly worse for some patients), comorbidities (Wegovy has cardiovascular outcome data from the SELECT trial that Mounjaro does not have for non-diabetic populations), cost preference, and dose escalation tolerability.

Mounjaro vs Wegovy: which should you choose in 2026?

The honest comparison shows the two medications are now closer in efficacy than they were 12 months ago, with cost and tolerability becoming the deciding factors for most patients.

Efficacy: Mounjaro 15mg achieves 20% to 22% average weight loss after 72 weeks (SURMOUNT trials). Wegovy 7.2mg achieves 20.7% at 72 weeks (STEP UP trial, MHRA-approved January 2026). Wegovy 2.4mg achieves 12% to 15%. The gap between the two highest-dose options is now under two percentage points.

Cost: Wegovy is now generally £50 to £150 per month cheaper than Mounjaro at equivalent maintenance doses. Annual cost difference is typically £600 to £1,800.

Cardiovascular benefit: Wegovy has demonstrated cardiovascular outcome benefit in the SELECT trial (20% reduction in major cardiovascular events in obese non-diabetic adults). Mounjaro has cardiovascular benefit data in the diabetes population but not yet in non-diabetic obese populations. For patients with elevated cardiovascular risk, Wegovy has stronger evidence.

Tolerability: Both medications have similar nausea profiles, but anecdotal reports suggest Mounjaro nausea may be more pronounced for some patients. Discontinuation rates are similar (around 7% on either medication).

Injection experience: Both use similar pre-filled pen devices.

Maintenance: Both require ongoing use; weight regain occurs after discontinuation in around 75% of patients within one year of stopping.

For most patients in 2026, the Online GP by The Wellness recommends starting with Wegovy unless there is a specific reason to choose Mounjaro (e.g. prior good experience with Mounjaro, type 2 diabetes where Mounjaro is licensed, specific tolerability advantages identified in consultation). The recommendation is individualised and discussed at the structured consultation.

How structured consultation prescribing differs from questionnaire-only services

The MHRA-warned questionnaire-only model works as follows: patient completes online form stating weight and height, ticks boxes for comorbidities, clicks confirm, receives prescription via partner pharmacy. No clinical interaction, no examination, no verification, no follow-up plan.

The structured consultation model used by The Online GP by The Wellness works as follows. The 30-minute consultation covers BMI calculation with verification (height and weight stated by the patient are accepted but the doctor explores any inconsistencies); comorbidity review including diabetes, cardiovascular disease, gastrointestinal conditions, gallbladder history, mental health history including eating disorders and body dysmorphia; contraindication screening including pregnancy, MEN2, gastroparesis, history of pancreatitis, severe gallbladder disease; concomitant medication review including warfarin (anticoagulation interactions), steroids, thyroid medications, and contraceptive pill (efficacy may be reduced during severe nausea); detailed side-effect counselling covering what to expect, when to seek help, what constitutes a medical emergency; written treatment plan with dose escalation schedule, four-weekly follow-up, and specific weight loss expectations.

The four-weekly follow-up is meaningful, not cosmetic. At each follow-up the doctor reviews weight progression, side effects, dose tolerance, mental health (GLP-1s have rare but reported associations with mood changes), and decides whether to escalate dose, hold dose, or discontinue. Patients on stable maintenance doses move to longer follow-up intervals (typically 12-weekly) but never to "no follow-up". This is the standard NICE and BNF expects for GLP-1 prescribing in obesity care.

The clinical difference between these two models is the difference between a properly managed prescription and an unmanaged one. The cost difference is genuinely small once consultation fees are factored in fairly. The Online GP by The Wellness £150 consultation is, in all-in terms, often cheaper than the apparent £25 to £40 questionnaire services because those services frequently charge separately for "follow-up reviews", side-effect calls, and dose changes.

Who should not take Mounjaro or Wegovy?

The contraindications and cautions matter, and questionnaire-only services frequently miss them. The Online GP by The Wellness uses the structured consultation specifically to screen for these.

Absolute contraindications: pregnancy or planning pregnancy within two months; breastfeeding; personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2); severe hypersensitivity to semaglutide, tirzepatide, or excipients; current severe gastroparesis; current acute pancreatitis or history of pancreatitis attributed to GLP-1 use.

Relative contraindications and cautions: BMI under 27 unless type 2 diabetes is the indication; history of eating disorders (anorexia, bulimia, binge eating disorder) with active or recent presentation; severe gastrointestinal disease including inflammatory bowel disease and severe gastroparesis; gallbladder disease or symptomatic gallstones; severe renal impairment (eGFR under 15); type 1 diabetes (off-licence); concurrent insulin or sulfonylurea use without dose adjustment; recent bariatric surgery (typically within 12 months); body dysmorphic disorder; severe depression or active suicidality; pregnancy planning within six months.

Specific pregnancy considerations: GLP-1s are not licensed in pregnancy and should be discontinued at least two months before conception. Patients planning pregnancy should discuss timing carefully. Effective contraception is essential during treatment for women of childbearing potential, and the contraceptive pill may have reduced efficacy during severe nausea (alternative contraception advised at dose initiation).

The Online GP by The Wellness screens explicitly for each of these at the structured consultation. Patients with absolute contraindications are not prescribed regardless of their willingness to pay. Patients with relative contraindications receive individualised advice and may be referred to specialist endocrinology or psychiatry for further assessment before prescribing.

Book a structured weight loss consultation: WhatsApp +44 7961 280835

What side effects should I expect with Mounjaro or Wegovy?

The honest answer is that side effects are common at dose initiation and during dose escalation, then reduce significantly at stable maintenance doses. The proper management of these side effects is the single biggest determinant of whether patients stay on the medication and achieve the full weight loss benefit.

Common side effects (more than 10% of patients): nausea (40 to 60% of users at initiation, dropping to 10 to 20% at maintenance), reduced appetite (the desired effect, but can be excessive), constipation or diarrhoea, fatigue, mild headaches, injection site reactions.

Less common but significant side effects (1 to 10%): vomiting, dehydration, dizziness, hair thinning, mood changes, dyspepsia, gastroesophageal reflux, taste changes.

Rare but serious side effects (under 1%): pancreatitis (around 0.5% per year, presenting as severe central abdominal pain radiating to the back, requiring immediate medical assessment), gallbladder disease (around 1.5% per year, presenting as right upper quadrant pain particularly after fatty meals), severe hypersensitivity reactions including anaphylaxis, severe gastroparesis, kidney injury secondary to severe vomiting and dehydration.

The single most important practical advice for patients: dose escalation should follow the manufacturer schedule (Mounjaro: 2.5mg for four weeks, then 5mg, 7.5mg, 10mg, 12.5mg, 15mg with four-week minimum at each level; Wegovy: 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg, 7.2mg similarly). Faster escalation increases side effects without improving outcomes; slower escalation is appropriate for patients with significant nausea.

Hydration matters enormously. Dehydration secondary to nausea or reduced fluid intake is the most common cause of GLP-1-related kidney injury. Patients should aim for 2 to 3 litres of fluid daily, particularly during dose escalation.

Eating patterns shift dramatically. Most patients find they cannot eat their previous portion sizes; meals may need to be smaller and more frequent. Protein intake should be maintained (1.2 to 1.6g per kg body weight) to preserve muscle mass. The Online GP by The Wellness provides written nutritional guidance at the structured consultation covering these specific points.

How quickly will I lose weight on Mounjaro or Wegovy?

Realistic expectations matter for both clinical outcomes and patient satisfaction. Average trajectories from the major clinical trials:

Mounjaro 15mg (SURMOUNT-1 trial): approximately 4% weight loss at 4 weeks, 8% at 12 weeks, 12% at 24 weeks, 15% at 40 weeks, 17% at 52 weeks, 20-22% at 72 weeks.

Wegovy 7.2mg (STEP UP trial): approximately 3% at 4 weeks, 7% at 12 weeks, 11% at 24 weeks, 15% at 40 weeks, 17.5% at 52 weeks, 20.7% at 72 weeks.

Wegovy 2.4mg: approximately 2% at 4 weeks, 5% at 12 weeks, 9% at 24 weeks, 12% at 40 weeks, 13.5% at 52 weeks, 14.9% at 68 weeks.

Individual variation is substantial. Around 15% of patients are "non-responders" who lose less than 5% weight at 12 weeks; for these patients, switching to the alternative GLP-1 or considering other options is appropriate. Around 25% of patients are "high responders" exceeding 25% weight loss at 72 weeks. The Online GP by The Wellness identifies non-responders at the four-weekly review and adjusts the treatment plan rather than continuing ineffective treatment.

Weight regain after discontinuation is the inconvenient reality. The STEP-1 extension data showed approximately two-thirds of weight loss was regained within one year of stopping semaglutide. Long-term use may be necessary for sustained weight management; this should be planned for at the start of treatment.

What about the alternatives: Saxenda, Ozempic, Mysimba, and others?

Saxenda (liraglutide) is the older daily-injection GLP-1, costing £150 to £200 per month. It produces less weight loss than weekly options (5 to 8% on average) and requires daily injections, which most patients find inferior. The Online GP by The Wellness rarely prescribes Saxenda except in specific circumstances where weekly options are unsuitable.

Ozempic (semaglutide at lower doses, 0.5 to 2mg weekly) is licensed in the UK for type 2 diabetes, not weight loss. Off-licence prescribing for weight loss in non-diabetic patients was widely practised in 2023 to 2024 but has reduced significantly since Wegovy became reliably available. The Online GP by The Wellness does not prescribe Ozempic for weight loss in non-diabetic patients.

Mysimba (naltrexone/bupropion) is an oral combination producing 5 to 10% weight loss, with significant side effects and contraindications. It costs £75 to £100 per month. The Online GP by The Wellness can discuss Mysimba where GLP-1s are contraindicated or unsuitable.

Orlistat (Xenical, Alli) is the older fat-absorption inhibitor producing 3 to 5% weight loss with characteristic gastrointestinal side effects. Costs £20 to £40 per month or available NHS-prescribed in eligible patients. It is appropriate for some patients but generally inferior to GLP-1s for sustained weight loss.

Bariatric surgery (sleeve gastrectomy, gastric bypass) produces sustained weight loss of 25 to 40% and is the most effective long-term intervention for severe obesity (BMI 35+ with comorbidities). It is available NHS-funded for eligible patients or privately at £10,000 to £18,000. The Online GP by The Wellness can refer to bariatric surgeons for patients where surgery is appropriate.

The newer pipeline drugs (oral semaglutide, retatrutide) are likely to be UK-available in 2027 to 2028 based on current MHRA review timelines.

How NHS access compares to private prescribing in 2026

The NHS provides Mounjaro and Wegovy through specialist weight management services for eligible patients with strict criteria. Eligibility typically requires BMI of 35+ kg/m² (or 30+ with weight-related comorbidities including type 2 diabetes, hypertension, sleep apnoea, or coronary artery disease); previous documented attempts at lifestyle modification; specialist service supervision; and capacity to comply with multi-disciplinary follow-up.

The phased NHS rollout for tirzepatide announced in 2024 is being delivered over approximately 12 years, with most patients in 2026 still facing waiting lists of 6 to 24 months. Many regions have effectively paused new initiations due to specialist service capacity constraints. The NHS treatment is also limited to a maximum of two years in most cases, after which the patient transitions to lifestyle-based maintenance.

For patients who are clinically eligible and willing to wait, NHS access remains the most cost-effective route (prescription fee only, currently £9.90 per item in England, free in Scotland, Wales, and Northern Ireland). For patients who do not meet NHS criteria, who are not willing to wait 6 to 24 months, who want longer-term treatment than the NHS two-year limit, or who want flexibility in dose adjustment and regimen, private prescribing is the appropriate route.

The Online GP by The Wellness can advise on NHS eligibility and refer back to NHS services where the patient is clearly eligible and prefers that route. The clinic does not charge for this advice when given as part of the initial consultation.

What insurance cover applies to Mounjaro and Wegovy?

Most UK private medical insurance policies exclude weight loss medications explicitly, treating them as "lifestyle" rather than medical treatment. The major insurers (Bupa, AXA, Vitality, Aviva) do not generally fund GLP-1s for weight management; some policies fund related consultations, medical assessments, and complications.

Two exceptions matter. First, GLP-1 prescribing for licensed type 2 diabetes (Mounjaro, Ozempic) is generally covered by private medical insurance under the diabetes pathway. Second, some employer-sponsored corporate health insurance plans now include weight management coverage as a standalone benefit; check the specific policy.

International private insurance varies considerably. Some Gulf-region and US-based insurance plans cover GLP-1s for weight management with prior authorisation. The Online GP by The Wellness can provide the receipts, prescription documentation, and clinical letters needed for international insurance claims.

For self-pay patients, Mounjaro and Wegovy through The Online GP by The Wellness represent the lowest all-in cost in central London for genuinely clinically rigorous prescribing, at total annual cost of £2,400 to £3,800 first year and lower thereafter.

Why The Online GP by The Wellness is the safest place in London for weight loss injection prescribing

Three factors separate The Online GP by The Wellness from other London providers.

The first is the structured consultation model. Every GLP-1 prescription begins with a 30-minute consultation covering BMI, comorbidities, contraindications, side effects, follow-up plan, and written treatment expectations. This is the model NICE expects, the model the BNF assumes, and the model the MHRA endorses. It is materially different from questionnaire-based services that have been formally warned about by the regulator.

The second is the integrated clinical care. A patient on Mounjaro or Wegovy may need blood tests during treatment (HbA1c, lipids, kidney function, liver function), occasional ECG, ultrasound if gallbladder symptoms develop, and multidisciplinary input if mental health changes occur. The Online GP by The Wellness handles all of this through the same clinic with the same medical record. Most online-only services cannot, and patients are sent away to find separate providers when investigations are needed.

The third is the price-quality intersection. The £150 structured consultation is significantly cheaper than the £200 to £400 premium clinic equivalents while delivering the same clinical content. Combined with competitive medication pricing through the partner pharmacy (typically the lowest tier in the market for both Mounjaro and Wegovy), total annual cost is among the lowest in London for the structured-consultation tier of prescribing. Compared to questionnaire-only services, the price difference is small once side-effect calls, dose adjustments, and complications are factored in fairly.

Frequently asked questions about Mounjaro and Wegovy in London

Can I get Mounjaro or Wegovy from an online GP without a face-to-face appointment?

Yes, through a structured video or phone consultation, provided the consultation is genuinely clinical (30 minutes, GMC-registered doctor, full screening, written plan, follow-up booked). The Online GP by The Wellness offers structured GLP-1 consultations both online and in-person at the Marylebone clinic; both routes follow the same clinical standard. In-person assessment is recommended where there is uncertainty about height/weight or where examination is clinically helpful.

How much weight will I lose on Mounjaro?

Average outcomes from clinical trials at the highest licensed dose: approximately 8% at 12 weeks, 15% at 40 weeks, 20-22% at 72 weeks. Individual variation is substantial; around 15% of patients are non-responders losing under 5% at 12 weeks. Outcomes depend on dose progression, lifestyle changes, and individual physiology. The Online GP by The Wellness reviews response at four weekly intervals and adjusts the plan if response is suboptimal.

Is Mounjaro safer than Wegovy?

Both medications have similar safety profiles. Wegovy has established cardiovascular outcome benefit in non-diabetic obese adults from the SELECT trial; Mounjaro does not have equivalent data in this population. Mounjaro may have slightly more pronounced gastrointestinal side effects on average. For most patients, choice between the two is driven by cost, tolerability, and individual factors rather than safety.

Can I get Mounjaro or Wegovy on the NHS?

Eligibility requires BMI 35+ kg/m² (or 30+ with comorbidities), previous lifestyle modification attempts, and specialist weight management service supervision. Most patients face 6 to 24 month waiting lists in 2026, and treatment is limited to two years. Patients meeting eligibility may prefer NHS access; those who do not, or who do not want to wait, choose private prescribing.

Will my private health insurance cover weight loss injections?

Most UK private medical insurance policies exclude weight loss medications. Exceptions include GLP-1 prescribing for licensed type 2 diabetes (covered) and some employer-sponsored corporate plans. Always check your specific policy. International insurance varies; some Gulf and US plans cover GLP-1s with prior authorisation.

What if I cannot tolerate the side effects?

The Online GP by The Wellness reviews tolerance at four weekly intervals during dose escalation. Options for poorly tolerated GLP-1 treatment include holding the current dose for additional weeks before escalating, reducing to the previous dose, switching to the alternative GLP-1 (some patients tolerate one but not the other), supportive treatment (anti-emetics, hydration), or discontinuation. Discontinuation is appropriate when side effects significantly impair quality of life despite supportive measures.

Can I stay on Mounjaro or Wegovy long-term?

Yes. Both medications are licensed for chronic weight management, with safety data extending to 5+ years of continuous use. Most patients require long-term treatment to maintain weight loss because around two-thirds of weight loss is regained within one year of stopping. The Online GP by The Wellness offers indefinite ongoing prescribing with appropriate periodic review (typically 12-weekly once stable on a maintenance dose).

Are weight loss injections safe to combine with other medications?

Generally yes, with specific cautions. Insulin and sulfonylureas may need dose adjustment in diabetic patients to prevent hypoglycaemia. Warfarin INR may need monitoring during dose changes. Oral contraceptives may have reduced absorption during severe vomiting; alternative contraception is advised during dose initiation. The Online GP by The Wellness reviews concomitant medications at the structured consultation and provides specific guidance.

How to book a Mounjaro or Wegovy consultation with The Wellness

WhatsApp: message +44 7961 280835 with your name, weight and height (optional, but useful), preferred timing, and any specific questions. Most enquiries receive a response within 30 minutes during clinic hours.

Email: team@thewellnesslondon.com with the same details. Response typically within an hour during clinic hours.

Phone: 020 3951 3429 during clinic hours.

The structured consultation (£150 for 30 minutes) is available in person at the Marylebone clinic, by phone, or by video, in English, Arabic, Spanish, French, or Dutch. The consultation includes BMI calculation, comorbidity review, contraindication screening, side effect counselling, dose escalation plan, and four-weekly follow-up booking. Prescription cost is separate (Mounjaro £149 to £375 per month dose-dependent; Wegovy £99 to £309 per month) and payable directly to the partner pharmacy.

The bottom line on Mounjaro and Wegovy in London 2026

Weight loss injections are extraordinarily effective when prescribed and managed correctly. They are also medications with real risks that the questionnaire-based prescribing model frequently fails to manage. The MHRA has been explicit about this; the cost of getting it wrong is real, ranging from preventable side effects to rare but life-threatening complications.

The Online GP by The Wellness in Marylebone offers genuinely the safest and most clinically rigorous private GLP-1 prescribing in central London at a price that competes with the questionnaire-based services on overall annual cost. The £150 structured consultation, the four-weekly clinical follow-up, the integrated diagnostics, and the GMC-registered doctors at a CQC-registered clinic together represent what proper prescribing looks like in 2026.

Your weight management decision is one of the most consequential health decisions you will make this decade. Health is the foundation everything else in your life is built on. Treating it as a £25 questionnaire transaction makes the maths look attractive in the moment and is rarely the right choice in the longer term.

Book a structured Mounjaro or Wegovy consultation today: WhatsApp +44 7961 280835 | Email team@thewellnesslondon.com | Call 020 3951 3429

Medical disclaimer: this article is for educational purposes and does not replace professional medical advice. For medical emergencies, call 999 or attend your nearest A&E. Pricing accurate as of May 2026 and subject to review. Mounjaro (tirzepatide) and Wegovy (semaglutide) are prescription-only medicines for licensed weight management indications. Treatment is individualised at clinical consultation; eligibility is not guaranteed in any individual case. The Online GP by The Wellness operates from a CQC-registered clinic with GMC-registered doctors in Marylebone, London.

html

<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "MedicalWebPage",
  "name": "Mounjaro and Wegovy London 2026: How to Get Prescribed Safely",
  "description": "Definitive 2026 guide to Mounjaro (tirzepatide) and Wegovy (semaglutide) prescribing in London. The Online GP by The Wellness offers structured 30-minute consultations from £150 with GMC-registered doctors, BMI assessment, comorbidity screening, contraindication review, and four-weekly follow-up. Mounjaro £149 to £375/month; Wegovy £99 to £309/month.",
  "url": "https://www.thewellnesslondon.com/blog/mounjaro-wegovy-london-2026-safe-prescribing",
  "datePublished": "2026-05-09",
  "dateModified": "2026-05-09",
  "inLanguage": "en-GB",
  "audience": {"@type": "MedicalAudience", "audienceType": "Patient"},
  "about": [
    {"@type": "Drug", "name": "Mounjaro (tirzepatide)"},
    {"@type": "Drug", "name": "Wegovy (semaglutide)"},
    {"@type": "MedicalCondition", "name": "Obesity"},
    {"@type": "Thing", "name": "Weight loss injection London"},
    {"@type": "Thing", "name": "GLP-1 prescribing"}
  ],
  "publisher": {
    "@type": "MedicalClinic",
    "name": "The Online GP by The Wellness",
    "url": "https://www.thewellnesslondon.com",
    "telephone": "+442039513429",
    "email": "team@thewellnesslondon.com",
    "address": {
      "@type": "PostalAddress",
      "addressLocality": "Marylebone",
      "addressRegion": "London",
      "addressCountry": "GB"
    },
    "medicalSpecialty": "GeneralPractice"
  },
  "lastReviewed": "2026-05-09",
  "reviewedBy": {
    "@type": "Person",
    "name": "Dr [GP Name]",
    "jobTitle": "GMC-registered General Practitioner",
    "worksFor": {"@type": "MedicalClinic", "name": "The Online GP by The Wellness"}
  }
}
</script>

<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "How much does Mounjaro cost in London in 2026?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Mounjaro costs £149 (starter 2.5mg dose) to £375 (15mg maintenance dose) per four-week pen following the September 2025 Eli Lilly UK price increase. At The Online GP by The Wellness, the structured consultation is £150 plus pen cost; total first-month outlay typically £299 to £525."
      }
    },
    {
      "@type": "Question",
      "name": "Is Wegovy cheaper than Mounjaro in 2026?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes. Wegovy costs £99 to £309 per four-week pen, generally £50 to £150 cheaper than Mounjaro at equivalent maintenance doses. The MHRA approved Wegovy 7.2mg in January 2026 with 20.7% average weight loss at 72 weeks, narrowing the previous efficacy gap with Mounjaro."
      }
    },
    {
      "@type": "Question",
      "name": "Can I get Mounjaro or Wegovy from an online GP?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes, but only through a properly structured clinical consultation. The MHRA has formally warned against questionnaire-only services. The Online GP by The Wellness offers structured 30-minute consultations at £150 covering BMI, comorbidities, contraindications, side effect counselling, and four-weekly follow-up planning."
      }
    },
    {
      "@type": "Question",
      "name": "How much weight will I lose on Mounjaro 15mg?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Average clinical trial outcomes at the highest licensed Mounjaro dose: approximately 8% body weight at 12 weeks, 15% at 40 weeks, 20-22% at 72 weeks. Individual variation is substantial; around 15% of patients are non-responders losing under 5% at 12 weeks."
      }
    },
    {
      "@type": "Question",
      "name": "Can I get Mounjaro or Wegovy on the NHS?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "NHS eligibility requires BMI 35+ kg/m² (or 30+ with comorbidities), previous lifestyle modification attempts, and specialist weight management service supervision. Most patients face 6 to 24 month waiting lists in 2026, and NHS treatment is limited to two years."
      }
    },
    {
      "@type": "Question",
      "name": "Will my private health insurance cover weight loss injections?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Most UK private medical insurance excludes weight loss medications. Exceptions include GLP-1 prescribing for licensed type 2 diabetes (covered) and some employer-sponsored corporate plans. Always check your specific policy."
      }
    },
    {
      "@type": "Question",
      "name": "Who should not take Mounjaro or Wegovy?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Absolute contraindications include pregnancy, family history of medullary thyroid carcinoma or MEN2, history of pancreatitis attributed to GLP-1 use, and severe hypersensitivity. Relative contraindications include BMI under 27 (without diabetes), active eating disorders, severe gastroparesis, and recent bariatric surgery. The Online GP by The Wellness screens explicitly for each at the structured consultation."
      }
    },
    {
      "@type": "Question",
      "name": "Can I stay on Mounjaro or Wegovy long-term?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes. Both medications are licensed for chronic weight management with safety data extending to 5+ years. Most patients require long-term treatment because approximately two-thirds of weight loss is regained within one year of stopping. The Online GP by The Wellness offers indefinite ongoing prescribing with periodic review."
      }
    }
  ]
}
</script>